Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: a test-negative case

Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: a test-negative case–control study

Published:2023-12 Issue:12 Volume:11 Page:1089-1100
ISSN:2213-2600
Container-title:The Lancet Respiratory Medicine
language:en
Short-container-title:The Lancet Respiratory Medicine

Author:

Tartof Sara Y,Slezak Jeff M,Puzniak Laura,Hong Vennis,Frankland Timothy B,Ackerson Bradley K,Xie Fagen,Takhar Harpreet,Ogun Oluwaseye A,Simmons Sarah,Zamparo Joann M,Valluri Srinivas R,Jodar Luis,McLaughlin John M

Funder

Pfizer

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference36 articles.

1. Effectiveness and durability of the BNT162b2 vaccine against Omicron sublineages in South Africa;Collie;N Engl J Med,2022

2. Effectiveness of Monovalent mRNA Vaccines Against COVID-19–Associated Hospitalization Among Immunocompetent Adults During BA.1/BA.2 and BA.4/BA.5 Predominant Periods of SARS-CoV-2 Omicron Variant in the United States — IVY Network, 18 States, December 26, 2021–August 31, 2022

3. Immunocompromise and durability of BNT162b2 vaccine against severe outcomes due to omicron and delta variants;Tartof;Lancet Respir Med,2022

4. Is COVID-19 seasonal? A time series modeling approach;Wiemken;medRxiv,2022

5. Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster;Kurhade;Nat Med,2022

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative effectiveness of bivalent BA.4–5 or BA.1 mRNA booster vaccines among immunocompromised individuals across three Nordic countries: A nationwide cohort study;Journal of Infection;2024-10

2. Modeling memory B cell responses in a lymphoid organ-chip to evaluate mRNA vaccine boosting;Journal of Experimental Medicine;2024-09-06

3. Vaccination against COVID-19 in a post-pandemic era;COVID-19: An Update;2024-09-01

4. Post-vaccination, post-infection and hybrid immunity against severe cases of COVID-19 and long COVID after infection with SARS-CoV-2 Omicron subvariants, Czechia, December 2021 to August 2023;Eurosurveillance;2024-08-29

5. Long-Term Safety and Immunogenicity of AZD1222 (ChAdOx1 nCoV-19): 2-Year Follow-Up from a Phase 3 Study;Vaccines;2024-08-03